Drugs / GANCOTAMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02735798 | Apr 2016 → Jun 2017 | metastatic malignant neoplasm in the brain | Pamela Munster | Withdrawn | No outcome recorded Stop: Business |
| Phase 11 trial | ||||||
| Phase 1 | NCT01304797 | Mar 2011 → Aug 2016 | breast cancer | Merrimack Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02213744 | Jul 2014 → Dec 2016 | HER2 positive breast carcinoma | Merrimack Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GANCOTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833344 ↗ |
| Known as | MM-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02213744 ↗ |
| Action | Inhibit | “DNA topoisomerase II alpha inhibitor” CHEMBL3833344 ↗ |
| Modality | Other / unclassified | “64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin” PMID 28298546 ↗ Mar 2017 |
| Route | Intravenous | “Intravenously Administered MM-302” NCT01304797 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 binding agent” CHEMBL3833344 ↗ |
| Target | TOP2A | “DNA topoisomerase II alpha inhibitor” CHEMBL3833344 ↗ |